PR Newswire

    Our goal is to enable the global flow of compute, and that means every cluster we deliver has to perform, no matter where the capacity comes from. Standardizing on WEKA NeuralMesh has given our customers hyperscaler-grade consistency with open-market flexibility at the storage and memory layer, where performance is won or lost,” said Wil Moushey, CEO at Andromeda. “Idle GPUs are throttling the pace of AI innovation. WEKA helps us ensure every GPU we manage is earning its keep.”

    “I am honored to join the Continuity Biosciences Board of Directors at such a pivotal time in the Company’s development,” said Papoutsis. “Continuity has assembled an outstanding management team, scientific advisors, and Board while building an innovative portfolio of precision drug delivery technologies across multiple therapeutic areas. I look forward to supporting the Company’s long-term strategy, helping expand its strategic partnerships, and contributing to its missions of improving outcomes for patients.”

    Nitinotes Ltd., developer of the EndoZip™ Automated Suturing System for Endoscopic Sleeve Gastroplasty (ESG), today announced completion of the first study procedures at Orlando Health in the Company’s pivotal U.S. EASE™ Investigational Device Exemption (IDE) trial, further expanding participation among leading centers specializing in both bariatric surgery and endoscopic obesity care.